正清风痛宁制剂治疗慢性肾小球肾炎随机对照试验的系统评价和Meta分析

Systematic evaluation and meta-analysis of randomized controlled trials of Zhengqing Fengtongning preparation in the treatment of chronic glomerulonephritis

目的:评价正清风痛宁制剂治疗慢性肾小球肾炎(chronic glomerulonephritis,CGN)的疗效与安全性。方法:计算机检索PubMed、CoChrane library、Embase、中国知网、万方、维普,查找正清风痛宁制剂治疗CGN随机对照试验(randomized controlled trials,RCTs),按照CoChrane系统评价方法,采用Revman 5.3软件进行分析。结果:纳入5篇随机对照试验354例患者,分析显示减少蛋白尿方面,正清风痛宁制剂加载西药治疗组疗效优于西药对照组,且正清风痛宁制剂治疗组优于雷公藤多甙对照组。应用正清风痛宁制剂可能会引起胃肠道反应、皮疹等,但多数在停药或药物调整后恢复正常。结论:正清风痛宁制剂治疗CGN具有减少尿蛋白作用,安全性较好。但鉴于纳入研究方法学质量较低,临床需要大样本、多中心、高质量的随机对照试验加以验证。

Objective:To systematically evaluate the effectiveness and safety of Zhengqing Fengtongning in the treatment of chronic glomerulonephritis.Methods:Data of clinical randomized controlled trials of Zhengqing Fengtongning preparation in the treatment of chronic glomerulonephritis were collected by searching the electronic databases including Pubmed、Cochrane Library、Embase、CNKI、Wangfang and VIP.Cochrane systematic evaluation was used to evaluate the methodological quality of the included studies and Meta-analysis was performed with RevMan 5.3 software.Results:A total of 5 RCTs including 354 patients met the inclusion criteria.In terms of reducing urinary protein,the effect of Zhengqing Fengtongning preparation combined with western medicine treatment group was better than western medicine control group,and Zhengqing fengtongning preparation treatment group was superior to tripterygium glycosides control group.Zhengqing Fengtongning preparation might cause abnominal discomfort,rash,etc.However,most of reaction returned to normal after stopping the drug or adjusting the drug.Conclusion:Zhengqing Fengtongning in the treatment of chronic glomerulonephritis could significantly reduced proteinuria and had a good security.Due to the low methodological quality,it is still necessary to carry out more randomized controlled clinical trials,that of multi-center,large-scale and high quality,to verify the above conclusions.